Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Prostatic Neoplasms 2Ovarian Neoplasms 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Solid Tumor 1Peripheral Nervous System Diseases 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, T-Cell, Cutaneous 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Head and Neck Neoplasms 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Sorafenib 121Nivolumab 36pembrolizumab 32Bevacizumab 28lenvatinib 27Doxorubicin 23Radiosurgery 21Radiofrequency Ablation 20Oxaliplatin 20Hepatectomy 18Fluorouracil 15Capecitabine 15Magnetic Resonance Spectroscopy 14atezolizumab 13Leucovorin 13Cisplatin 13Gemcitabine 11Erlotinib Hydrochloride 11tislelizumab 9Sirolimus 9Radiotherapy 9Irinotecan 9Ipilimumab 9cabozantinib 8Liver Transplantation 8regorafenib 7Ramucirumab 7Folfox protocol 7Embolization, Therapeutic 7sintilimab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoma, Hepatocellular × BID protein, human × Clear all
NCT03516071 2019-09-04

A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC

Zai Lab (Hong Kong), Ltd.

Phase 2 Completed
90 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡